4.1 Article

Angiosarcoma associated with radiation therapy after treatment of breast cancer. Retrospective study on ten years

Journal

CANCER RADIOTHERAPIE
Volume 25, Issue 2, Pages 114-118

Publisher

ELSEVIER
DOI: 10.1016/j.canrad.2020.05.020

Keywords

Breast cancer; Radiation therapy; Angiosarcoma; Surgery

Ask authors/readers for more resources

This study evaluated rare cases of angiosarcoma associated with radiation therapy in eastern Belgium, finding a median latency of several years and a relatively low incidence rate. Patients were typically treated with surgery, with survival rates decreasing over time.
Purpose. - The breast sarcoma induced by radiation therapy is rare but increasing, given the increased long-term survival of patients receiving radiation therapy. Fibro sarcoma, histiocytofibroma and angiosarcoma are the most common breast sarcoma. Angiosarcoma is the most common after breast cancer treated by radiation therapy, often diagnosed too late, with a severe prognosis and a high rate of recurrence. However, because of the low incidence of angiosarcoma associated with radiation therapy (AAR), the benefit of radiation therapy in breast cancer treatment outweighs the risk to develop angiosarcoma. The aim of this study is to evaluate these rare cases of AAR diagnosed in eastern Belgium in comparison to the data from the literature. Patients and methods. - Nine cases of AAR after radiation for breast ductal carcinoma were included in this retrospective study. AAR was diagnosed according to Cahan criteria between January 2007 and December 2016. Latency, incidence, management and prognosis are comparable to the literature. Results, conclusion. - The median latency was 10 (4-24) years, the incidence of AAR in the East Belgian area was 0.09% of the patients irradiated on the same period. Patients were treated by surgery with wide local excision with or without reconstructive surgery, without radiotherapy and chemotherapy treatment. Kaplan-Meier analysis showed median overall survival of 61.8 months, patient survival of 55.6% at one year and 29.6% at five years. With the constant progress of medicine and its technologies, it would be possible to limit the occurrence of AAR or to diagnose it at an earlier stage. (C) 2020 Societe francaise de radiotherapie oncologique ( SFRO). Published by Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available